MorphoSys AG (MOR) News

MorphoSys AG (MOR)

Today's Latest Price: $26.86 USD

0.18 (0.67%)

Updated Nov 23 5:22pm

Add MOR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter MOR News Items

MOR News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest MOR News From Around the Web

Below are the latest news stories about MorphoSys AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

MorphoSys's CFO to step down

MorphoSys (MOR) has announced that its CFO Jens Holstein, will step down, effective December 31. The company has commenced a search process for the new CFO....

Seeking Alpha | September 30, 2020

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript

MorphoSys AG (MOR) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Anja Pomrehn - Head of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Research and Development Officer Roland Wandeler - COO Conference Call Participants Jason Butler - JMP Securities...

SA Transcripts on Seeking Alpha | August 9, 2020

FDA OKs Incyte/Morphosys' tafasitamab for treatment-resistant lymphoma

Morphosys AG (MOR) and collaboration partner/licensee Incyte (INCY) announce the FDA nod for Monjuvi (tafasitamab-cxix), combined with lenalidomide, for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma ((DLBCL)) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell...

Seeking Alpha | August 1, 2020

Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

MorphoSys' Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.

Yahoo | July 30, 2020

MORNING BID-Fog, stall ... rally

The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."

Yahoo | July 15, 2020

MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 14, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today that its licensee Janssen Research & Development, ...

Yahoo | July 14, 2020

MorphoSys AG (MOR): Are Hedge Funds Right About This Stock?

The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

Yahoo | June 10, 2020

Anti-inflammatory and cancer drugs tested in UK as possible COVID-19 therapy

Two drugs used to treat inflammatory diseases and cancer are being tested as potential therapies for patients with COVID-19, the Universities of Birmingham and Oxford announced on Wednesday. Severe cases of COVID-19 are believed to be triggered by an over-reaction of the immune system, known as a cytokine storm, and researchers are investigating whether drugs that suppress certain elements of the immune system can play a role in arresting a rapid escalation of symptoms. Izana Bioscience's Namilumab, a monoclonal antibody already in late-stage tests to treat rheumatoid arthritis and an inflammatory disease called ankylosing spondylitis, is the first of four candidates in the CATALYST trial.

Yahoo | June 10, 2020

GSK begins U.S. test of experimental drug for pneumonia from COVID-19

Yahoo | June 9, 2020

AstraZeneca blood cancer drug shows signs of helping COVID-19 patients

AstraZeneca's cancer drug Calquence has shown initial signs of helping hospitalised COVID-19 patients get through the worst of the disease, as researchers scramble to repurpose existing treatments to help fight the deadly infection. Results from the preliminary research involving 19 patients, which was backed by the United States National Institutes of Health, encouraged the British drugmaker to explore the drug's new use in a wider clinical trial announced in April. Eleven patients had been on oxygen when they started the 10-14 day Calquence course and eight of them could afterwards be discharged, breathing independently, according to results in a paper co-authored by Astra's head of oncology research, Jose Baselga.

Yahoo | June 5, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.5799 seconds.